Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "LA"

8175 News Found

Abbott unveils new diabetes care formula amid rising global diabetes crisis
News | November 16, 2025

Abbott unveils new diabetes care formula amid rising global diabetes crisis

The new formulation features what Abbott calls a “triple care system,” anchored by a blend of nutrients aimed at supporting blood sugar control and metabolic health


ImmunoScape inks agreement with Cue Biopharma to launch next-gen cancer immunotherapy
Biopharma | November 16, 2025

ImmunoScape inks agreement with Cue Biopharma to launch next-gen cancer immunotherapy

The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies


Amcor launches ultra-light Shadow roll-on for next-gen beauty branding
Packaging | November 16, 2025

Amcor launches ultra-light Shadow roll-on for next-gen beauty branding

The new shadow roll-on delivers strong on-shelf presence with its modern rounded-base design


Caplin Point Laboratories’ subsidiary acquires land in Mexico
News | November 15, 2025

Caplin Point Laboratories’ subsidiary acquires land in Mexico

The investment in land is Rs. 19.85 crore


Zydus receives FDA final approval for Diroximel fumarate delayed-release capsules, 231 mg
Drug Approval | November 14, 2025

Zydus receives FDA final approval for Diroximel fumarate delayed-release capsules, 231 mg

Diroximel fumarate delayed-release capsules, 231 mg, are indicated for the treatment of relapsing forms of multiple sclerosis


Alembic receives USFDA final approval for Dexlansoprazole delayed-release capsules, 30 mg and 60 mg
Drug Approval | November 14, 2025

Alembic receives USFDA final approval for Dexlansoprazole delayed-release capsules, 30 mg and 60 mg

Dexlansoprazole delayed-release capsules are a proton pump inhibitor


UK MHRA finds gut microbiome research unreliable across labs
R&D | November 14, 2025

UK MHRA finds gut microbiome research unreliable across labs

False positive rates?ranged from 0% to 41%, meaning some labs incorrectly identified bacteria that weren’t present in the sample


LANXESS set to showcase cutting-edge infection control solutions
News | November 14, 2025

LANXESS set to showcase cutting-edge infection control solutions

LANXESS will highlight its commitment to combatting antimicrobial resistance by presenting science-based disinfection solutions


SpyGlass Pharma reports promising clinical trial results for glaucoma therapy
Biopharma | November 14, 2025

SpyGlass Pharma reports promising clinical trial results for glaucoma therapy

The data highlight sustained intraocular pressure (IOP) reduction, drop-free treatment outcomes, and strong visual performance